Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Nov 9:14:27-30.
doi: 10.1016/j.ymgmr.2017.10.013. eCollection 2018 Mar.

Parkinson's disease prevalence in Fabry disease: A survey study

Adina H Wise  1 , Amy Yang  2 , Hetanshi Naik  2 , Chanan Stauffer  2 , Natasha Zeid  2 , Christopher Liong  1 , Manisha Balwani  2 , Robert J Desnick  2 , Roy N Alcalay  1
Affiliations

Parkinson's disease prevalence in Fabry disease: A survey study

Adina H Wise et al. Mol Genet Metab Rep. .

Abstract

Recent research has suggested a possible link between Parkinson's disease (PD) and Fabry disease. To test this relationship, we administered a self-report and family history questionnaire to determine the prevalence of PD in Fabry disease patients and family members with likely pathogenic alpha-galactosidase A (GLA) mutations. A total of 90 Fabry patients (77 from the online survey and 13 from the Icahn School of Medicine at Mount Sinai (ISMMS)) were included in the analysis. Two of the Fabry disease patients who completed the online survey were diagnosed with PD (2/90, 2.2%). Among probands older than 60, 8.3% (2/24) were diagnosed with PD. Using Kaplan Meier survival analysis, the age-specific risk of PD by age 70 was 11.1%. Family history was available on 72 Fabry families from the online study and 9 Fabry families from ISMMS. Among these 81 families, 6 (7.4%) had one first degree relative who fit the criteria for a conservative diagnosis of PD. The results of this study suggest that there may be an increased risk of developing PD in individuals with GLA mutations, but these findings should be interpreted with caution given the limitations of the study design.

Keywords: Alpha-galactosidase A; Fabry disease; GLA; ISMMS, Icahn School of Medicine at Mount Sinai; Lysosomal storage disorder; Parkinson's disease.

PubMed Disclaimer

Similar articles

  • Prevalence of Fabry Disease among Patients with Parkinson's Disease.
    Lackova A, Beetz C, Oppermann S, Bauer P, Pavelekova P, Lorincova T, Ostrozovicova M, Kulcsarova K, Cobejova J, Cobej M, Levicka P, Liesenerova S, Sendekova D, Sukovska V, Gdovinova Z, Han V, Rizig M, Houlden H, Skorvanek M. Lackova A, et al. Parkinsons Dis. 2022 Jan 24;2022:1014950. doi: 10.1155/2022/1014950. eCollection 2022. Parkinsons Dis. 2022. PMID: 35111290 Free PMC article.
  • Enzymatic properties and clinical associations of serum alpha-galactosidase A in Parkinson's disease.
    Mizutani Y, Nawashiro K, Ohdake R, Tatebe H, Shima S, Ueda A, Yoshimoto J, Ito M, Tokuda T, Mutoh T, Watanabe H. Mizutani Y, et al. Ann Clin Transl Neurol. 2023 Sep;10(9):1662-1672. doi: 10.1002/acn3.51856. Epub 2023 Jul 26. Ann Clin Transl Neurol. 2023. PMID: 37496179 Free PMC article.
  • Genetic Screening of Anderson-Fabry Disease in Probands Referred From Multispecialty Clinics.
    Favalli V, Disabella E, Molinaro M, Tagliani M, Scarabotto A, Serio A, Grasso M, Narula N, Giorgianni C, Caspani C, Concardi M, Agozzino M, Giordano C, Smirnova A, Kodama T, Giuliani L, Antoniazzi E, Borroni RG, Vassallo C, Mangione F, Scelsi L, Ghio S, Pellegrini C, Zedde M, Fancellu L, Sechi G, Ganau A, Piga S, Colucci A, Concolino D, Di Mascio MT, Toni D, Diomedi M, Rapezzi C, Biagini E, Marini M, Rasura M, Melis M, Nucera A, Guidetti D, Mancuso M, Scoditti U, Cassini P, Narula J, Tavazzi L, Arbustini E. Favalli V, et al. J Am Coll Cardiol. 2016 Sep 6;68(10):1037-50. doi: 10.1016/j.jacc.2016.05.090. J Am Coll Cardiol. 2016. PMID: 27585509
  • Genotype and phenotype in Fabry disease: analysis of the Fabry Outcome Survey.
    Schaefer E, Mehta A, Gal A. Schaefer E, et al. Acta Paediatr Suppl. 2005 Mar;94(447):87-92; discussion 79. doi: 10.1111/j.1651-2227.2005.tb02119.x. Acta Paediatr Suppl. 2005. PMID: 15895718 Review.
  • The patient's perspective of Fabry disease – a report from the German Fabry Patient Support Group.
    Basalla D. Basalla D. In: Mehta A, Beck M, Sunder-Plassmann G, editors. Fabry Disease: Perspectives from 5 Years of FOS. Oxford: Oxford PharmaGenesis; 2006. Chapter 13. In: Mehta A, Beck M, Sunder-Plassmann G, editors. Fabry Disease: Perspectives from 5 Years of FOS. Oxford: Oxford PharmaGenesis; 2006. Chapter 13. PMID: 21290667 Free Books & Documents. Review.
See all similar articles

Cited by

See all "Cited by" articles

References

    1. Sidransky E., Lopez G. The link between the GBA gene and parkinsonism. Lancet Neurol. 2012;11:986–998. - PMC - PubMed
    1. Dagan E., Schlesinger I., Ayoub M., Mory A., Nassar M. The contribution of Niemann-Pick SMPD1 mutations to Parkinson disease in Ashkenazi Jews. Parkinsonism Relat. Disord. 2015;21:1067–1071. - PubMed
    1. Foo J.N., Liany H., Bei J.X., Yu X.Q., Liu J. Rare lysosomal enzyme gene SMPD1 variant (p.R591C) associates with Parkinson's disease. Neurobiol. Aging. 2013;34(2890):e2813–2895. - PubMed
    1. Gan-Or Z., Ozelius L.J., Bar-Shira A., Saunders-Pullman R., Mirelman A. The p.L302P mutation in the lysosomal enzyme gene SMPD1 is a risk factor for Parkinson disease. Neurology. 2013;80:1606–1610. - PMC - PubMed
    1. Alcalay R.N., Levy O.A., Wolf P., Oliva P., Zhang X.K. SCARB2 variants and glucocerebrosidase activity in Parkinson's disease. NPJ Park. Dis. 2016;2 - PMC - PubMed